Viracta Therapeutics, Inc. (VIRX) - Volume dana dhuwit perusahaan

Lambang korporat lan logo Viracta Therapeutics (VIRX)

Viracta Therapeutics (VIRX) leads the therapy of EBV-related oncological diseases by utilizing a unique method of virus activation and destruction. Patent protection ensures global growth potential and high margins. The company's cash balance demonstrates current liquidity, with the indicator standing at 0.00. The business is currently developing a pipeline of targeted drugs through the clinical trial stage.

Viracta Therapeutics, Inc. - Sisa dhuwit perusahaan VIRX (periode 04.07.2022 - 16.02.2025)

Rincian metrik keuangan lan pasar Viracta Therapeutics (VIRX)

Analisis kabeh metrik perusahaan:VIRX Viracta Therapeutics
Produk merek Viracta

For an investor assessing an issuer's solvency, this indicator serves as a measure of liquidity. The metric aggregates the volume of available cash and equivalents, reflecting the company's ability to cover short-term obligations without seeking external financing. For Viracta Therapeutics (VIRX), the value of 0.00 is critical, as outsourcing production to CMOs requires a constant influx of capital. By analyzing current cash reserves, one can assess the business's margin of safety.

Pesaing langsung

Volume dana dhuwit perusahaan ONC|HALO - Cadangan dhuwit perusahaan|Revolution Medicines - Dhuwit awis perusahaan|Volume dana dhuwit perusahaan Ascentage Pharma AAPG|CGON - Dana dhuwit perusahaan|Total volume dana dhuwit perusahaan URGN|BCAX: Volume dana dhuwit perusahaan|PSNL - Aset likuid perusahaan|ERAS (Erasca Inc) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Delcath Systems Inc DCTH|Dana dhuwit perusahaan YmAbs (YMAB)|Aset likuid perusahaan Aura Bio|Volume dana dhuwit perusahaan CADL (Candel Therapeutics Inc.)|accuray.com (ARAY) - Cadangan dhuwit perusahaan|SELLAS Life Sciences Group - Volume dana dhuwit perusahaan|ACTU - Volume dana dhuwit perusahaan|CTOR: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan TuHURA (HURA)|TARA (Protara Therapeutics Inc) - Volume dana dhuwit perusahaan|Fate Therapeutics, Inc. (FATE) - Aset likuid perusahaan|Dhuwit awis perusahaan WHWK (Aadi Bioscience, Inc.)|Aset likuid perusahaan TScan Therapeutics, Inc.|Volume dana dhuwit perusahaan CSBR (Champions Oncology Corp)|Gunggung dana dhuwit perusahaan XBIT (XBiotech USA)|CVM - Dana dhuwit perusahaan|Sisa dhuwit perusahaan OSTX (ostherapies.com)|Radiopharm Theranostics Ltd (RADX) - Dana dhuwit perusahaan|ARTV: Gunggung dana dhuwit perusahaan|ANL (adlainortye.com) - Volume dana dhuwit perusahaan|VERU: Sisa dhuwit perusahaan|Dhuwit awis perusahaan TPST (Tempest Tx)|Dhuwit awis perusahaan Xilio XLO|Volume dana dhuwit perusahaan RENB (Renovaro)|Volume dana dhuwit perusahaan Mural Bio MURA|Kairos Pharma Ltd - Volume dana dhuwit perusahaan|OnKure Therapeutics (OKUR) - Dhuwit awis perusahaan|GDTC: Volume dana dhuwit perusahaan|Curis Inc. - Sisa dhuwit perusahaan|Dana dhuwit perusahaan apollomicsinc.com|THAR: Sisa dhuwit perusahaan|Dana dhuwit perusahaan Advanced Biomed Corp (ADVB)|GNPX (Genprex, Inc) - Sisa dhuwit perusahaan|Volume dana dhuwit perusahaan CLDI (Calidi Biotherapeutics)|sunshinebiopharma.com (SBFM) - Cadangan dhuwit perusahaan|Xenetic Bio - Volume dana dhuwit perusahaan|SLRX (Salarius Pharmaceuticals, Inc.) - Dhuwit awis lan setara dhuwit awis perusahaan|PPBT: Volume dana dhuwit perusahaan|Dhuwit awis perusahaan American Oncology Network Inc|BGNE (beigene.com) - Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan CKPT (Checkpoint Therapeutics)|Dhuwit awis perusahaan ELEV (Elevation Oncology Inc.)|iCAD - Dhuwit awis lan setara dhuwit awis perusahaan|Ikena Oncology Inc. - Dhuwit awis perusahaan|Notable Labs Corp (NTBL) - Cadangan dhuwit perusahaan|MOR: Dhuwit awis perusahaan|NAYA - Volume dana dhuwit perusahaan|Ascentage Pharma (AAPGV) - Dana dhuwit perusahaan